Long-Term Risks Of Seroquel XR Will Be Focus Of Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca commits to a post-market study but says broadened indications for generalized anxiety disorder and major depressive disorder would not broaden the risks.
You may also be interested in...
Seroquel XR Might Get Second Line For Depression, Anxiety Despite Safety Worry
A second-line indication for AstraZeneca's Seroquel XR (quetiapine) in major depressive disorder and generalized anxiety disorder remains possible following a unanimous FDA advisory committee vote that the drug is not "acceptably safe" for the monotherapy claims in MDD and GAD that AstraZeneca had been seeking
Seroquel XR Might Get Second Line For Depression, Anxiety Despite Safety Worry
A second-line indication for AstraZeneca's Seroquel XR (quetiapine) in major depressive disorder and generalized anxiety disorder remains possible following a unanimous FDA advisory committee vote that the drug is not "acceptably safe" for the monotherapy claims in MDD and GAD that AstraZeneca had been seeking
Seroquel XR Needs Long-Term Safety Data For Depression, Anxiety Monotherapy – FDA Panel
AstraZeneca does gets recommendation for the atypical antipsychotic as adjunct therapy in major depressive disorder.